Sudeep Pharma Limited
IPO Details
Subscription
Lot Distribution
Reservation
Company Fin.
₹94(15.85%)
Premium (ELP)
Sudeep Pharma Limited's has transitioned to a publicly listed entity following its IPO debut on Nov 28, 2025 at the NSE, BSE exchange. The public offering successfully raised 1,50,92,749 Shares, consisting of 16,02,024 Sharesin new capital and ₹800.00 Cr in existing shareholder sales.
The IPO featured a competitive price range of ₹563 to ₹593 and minimum application size of 25 shares. Market reception was evidenced through subscription activity between Nov 21, 2025 and Nov 25, 2025, reflecting investor appetite for the offering.
Allotment of shares was completed on Nov 26, 2025, distributing equity to successful applicants. The listing marked the beginning of the company's journey as a publicly traded corporation, subject to market dynamics and regulatory oversight.
Investors can bid starting from the minimum lot size specified for this IPO, and only in multiples of that lot size. The table below shows the minimum and maximum investment for retail investors and HNIs in terms of lots, quantity, and amount.
Sudeep Pharma Limited, incorporated in 1989, is a global manufacturer of pharmaceutical excipients, food-grade minerals, and specialty nutrition ingredients, supplying over 200 products to customers in more than 100 countries. The company operates six manufacturing facilities with a total capacity of 50,000 MT, producing key minerals such as calcium, iron, magnesium, zinc, potassium, and sodium. With strong in-house R&D and pilot-scale labs, the company focuses on developing high-quality mineral salts and excipients across its pharmaceutical, food and nutrition, specialty ingredients, and triturates product segments. As of December 31, 2024, it employed 704 permanent staff.
Note : "Calculations for ‘Shares Offered’ and ‘Total Amount’ are based on the highest price in the issue price band."
- Strong Market Leadership with a Wide Product Range: A leading manufacturer of pharmaceutical, food, nutrition, and specialty ingredients (as of June 30, 2025), with strong expertise in mineral-based products, iron phosphate, and a broad portfolio of specialty food ingredients such as encapsulated preservatives.
- Advanced and Fully Compliant Manufacturing Setup: Operates four manufacturing facilities with 12 production lines across Gujarat and Ireland, covering 68,446 sq. meters and offering an annual capacity of 72,246 MT, ensuring efficient production and regulatory compliance.
- Innovation Driven by Strong R&D Capabilities: Equipped with two R&D centers and a team of 41 specialists focusing on particle engineering, shelf-life enhancement, nutrient bioavailability, and advanced formulation solutions, supported by modern equipment to drive technology improvements, sustainability, and product expansion.
- High Dependence on Key Customers: A major share of revenue is concentrated among a limited set of customers, making the business vulnerable to reduced orders or the loss of any key client, which could impact financial performance and cash flow.
- Strict Regulatory and Quality Compliance Requirements: Manufacturing units are regularly inspected and must meet standards prescribed by global agencies such as USFDA, EXCiPACT, FSSC, WHO-GMP, ISO, and HACCP. Any deviation, quality lapse, or non-compliance could lead to regulatory action and harm the company’s reputation.
- Risk of Operational Disruptions: Manufacturing and R&D activities face potential threats from equipment breakdowns, industrial accidents, regulatory issues, natural calamities, or outbreaks of infectious diseases. Any disruption or shutdown could negatively affect business operations, financial results, and liquidity.
- Sujit Jaysukh Bhayani
- Avani Sujit Bhayani
- Shanil Sujit Bhayani
- Sujeet Jaysukh Bhayani HUF
- Riva Resources Private Limited
- Bhayani Family Trust
Sudeep Pharma Limited
Link Intime India Private Limited